New company name and website

On May 15, 2020 MV BioTherapeutics reported the launch of the company website that provides most relevant information on the technology and pipeline of MV BioTherapeutics (Press release, MV BioTherapeutics, MAY 15, 2020, View Source [SID1234632273]). We have changed the original name of the company from MicroVaccines to MV BioTherapeutics (from now on MV).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"During the past years we have developed therapeutic live biotherapeutics with different mode of action as compared to the original live attenuated microbial vaccines, which were exemplified as microvaccines" says Dr. Fabio Grassi, founder and Chairman of MV.

"With two lead indications and potential future developments of this promising application, it was important to characterize the company as non-exclusively dedicated to vaccines that is a very specific pharmaceutical area."

The abbreviation MV is directly related to the two patented microorganisms ApyraMed and ApyraVax

Affibody and Inmagene Announce Strategic Partnership to Develop ABY-035 – A Phase 2 Drug Candidate with Best-in-Class Potential for Auto-Immune Diseases

On May 15, 2020 Affibody AB ("Affibody") and Inmagene Biopharmaceuticals ("Inmagene") reported a strategic partnership to develop and commercialize ABY-035, a bispecific molecule targeting Interleukin-17A (IL-17), for multiple auto-immune diseases (Press release, Affibody, MAY 15, 2020, View Source [SID1234575707]). Inmagene will be responsible for commercialization in mainland China, Hong Kong, Taiwan, and Macau (Greater China), and South Korea, as well as development activities in the Asia Pacific region, excluding Japan. Affibody will retain global commercial rights outside of Greater China and South Korea. The partners will work together to enroll patients into global registrational trials to support Biologics License Applications (BLAs) in multiple indications worldwide.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Affibody will receive a $10 million upfront payment and is eligible to receive up to $215.5 million in additional regulatory and sales milestones, plus royalties on sales in Inmagene’s commercialization territory. Additionally, Inmagene will share the global development costs of select clinical trials and be eligible to receive payments and royalties from Affibody relating to certain global development and commercialization milestones. Affibody will be responsible for the manufacturing and supply of ABY-035 for development and commercialization worldwide and is not precluded from additional collaboration and licensing agreements in territories not covered by this agreement.

Currently in Phase 2 development, ABY-035 is an innovative fusion protein targeting IL-17. ABY-035 combines Affibody’s proprietary protein therapeutics platform (Affibody technology), which confers greater potency in a small molecular format, and the Albumod technology which provides a long half-life. Together, these features provide the potential for best-in-class efficacy in a convenient, less frequent and at-home subcutaneous administration. In the ongoing Phase 2 Psoriasis Trial, ABY-035 has demonstrated a strong safety profile and clear clinical benefits.

"Based on ABY-035’s strong clinical data and significant advantages over antibody-based IL-17 therapies, we believe it has the best-in-class potential," said Jonathan Wang, Ph.D., Inmagene’s Chairman and CEO. "ABY-035 may provide affordable solutions to Chinese patients with high unmet medical needs and become a key pillar for Inmagene to establish a leadership position in China’s immunology related therapeutic areas."

With rich experience in bringing multiple relevant biologics targeting IL-17, IL-1, IL6, T cell and B cell to China as well as the US and Europe markets, the Inmagene clinical development team will work closely with Affibody to conduct global trials in multiple regions to shorten the development timelines. Inmagene will take the lead of the global development strategy and implementation in two indications.

"This creative alliance between Affibody and Inmagene is poised to deliver on ABY-035’s best-in-class potential by accelerating the time to commercialization across multiple indications and accessing a significant market opportunity in Greater China" said David Bejker, CEO of Affibody. "With the extensive track record of the Inmagene team, we will be able to leverage access to the Chinese market, providing additional opportunities for development and commercialization. The team’s vision of creating the leading Chinese immunology company is one we are excited to be a part of."

About ABY-035

ABY-035 is a novel bispecific agent, potently targeting both subunits of IL-17A as well as albumin, which has been specifically designed to utilize the strengths of Affibody’s technology platform to create a very small protein drug (18 kDa, an eighth of the size of an antibody) with very high apparent affinity to IL-17A (KD ~300fM) and antibody-like half-life due to the strong (KD ~50pM) binding affinity to serum albumin.

Accumulated patient data from ~150 psoriasis patients, some of which have been dosed for more than two years, support a safe and efficacious product profile with best-in-class potential.

ABY-035 is currently being evaluated in an open-label extension of the double-blinded, placebo controlled, 52 week, Phase 2 proof-of-concept study (AFFIRM-35, NCT03591887) which has enrolled 108 moderate-to-severe psoriasis patients in centers throughout Germany to evaluate the efficacy, safety and tolerability of ABY-035. The primary efficacy measure is PASI 90 at twelve weeks. Secondary endpoints include absolute and relative PASI-measures at weeks 12, 24, and 52; DLQI; itch and pain VAS; safety and tolerability, and pharmacokinetics.

In a Phase 1/2 study, ABY-035 demonstrated favorable safety and tolerability across multiple doses and dosing regimens with rapid and sustained efficacy in patients. The primary objective of this study was to evaluate mechanism of action, safety, tolerability and pharmacokinetics of ABY-035.

Heat Biologics Provides First Quarter 2020 Business Update

On May 15, 2020 Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company specialized in the development of novel therapeutic and prophylactic vaccines, including one for coronavirus COVID-19, reported that financial, clinical and operational updates for the first quarter ended March 31, 2020 (Press release, Heat Biologics, MAY 15, 2020, View Source [SID1234558125]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jeff Wolf, Chief Executive Officer of Heat Biologics, commented, "We continue to make progress advancing our unique COVID-19 vaccine utilizing our robust gp-96 vaccine platform in collaboration with researchers at University of Miami. We plan to commence preclinical testing for the COVID-19 vaccine this quarter and are finalizing our manufacturing plans, which we believe will help shorten the clinical timeline. Additionally, we are applying for grants to support clinical development of this program and are advancing collaboration discussions. Earlier this year we also announced a collaboration with the University of Miami to develop a proprietary COVID-19 point-of-care diagnostic test. We suspended this program due to the progress made by other diagnostic manufacturers utilizing a similar approach, and our desire to focus resources on our highly-differentiated COVID-19 vaccine. Nevertheless, in the process, we developed our own unique diagnostic intellectual property, and plan to opportunistically explore partnership opportunities around this technology."

"We also continue to achieve key milestones related to HS-110 in combination with Opdivo (nivolumab) in advanced non-small cell lung cancer (NSCLC). We recently announced that an abstract has been posted on The American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s (ASCO) (Free ASCO Whitepaper) website. We look forward to presenting additional data at the upcoming ASCO (Free ASCO Whitepaper) Conference on May 29. Importantly, given the strength of the data, we plan to initiate an end of Phase 2 Type B meeting with the FDA to discuss our registrational strategy.

"We ended the quarter with over $26 million of cash and short-term investments as of March 31, 2020, which we believe provides us significant resources to advance each of our programs," concluded Mr. Wolf.

Q1 2020 Financial Results

Research and development expenses decreased approximately 12.5% to $2.8 million for the quarter ended March 31, 2020 compared to $3.2 million for the quarter ended March 31, 2019.
General and administrative expense was $3.3 million for the quarters ending March 31, 2020 and 2019.
Net loss attributable to Heat Biologics was approximately $6.3 million, or ($0.11) per basic and diluted share for the quarter ended March 31, 2020 compared to a net loss of $5.7 million, or ($0.17) per basic and diluted share for the quarter ended March 31, 2019.
As of March 31, 2020, the Company had approximately $26.4 million in cash, cash equivalents and short-term investments.

VBI Vaccines Announces Upcoming Poster Presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting

On May 15, 2020 VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported that expanded immunologic and tumor response data from the ongoing Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) patients will be presented at the 2020 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, to be held June 22-24, 2020 (Press release, VBI Vaccines, MAY 15, 2020, View Source [SID1234558151]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In his presentation of the e-poster via an accompanying audio narrative, David E. Anderson, Ph.D., VBI’s Chief Scientific Officer, will describe how the highest dose of VBI-1901 in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) boosted cytomegalovirus (CMV) immunity, even in highly immunosuppressed patients. Moreover, a baseline biomarker was identified in patients in the Part A dose-ranging phase of the study that may help predict patients most likely to respond to, and derive clinical benefit from, treatment with VBI-1901. The correlation observed between baseline biomarker data and tumor response data in Part A of the trial was strengthened by the inclusion of additional patients in the Part B extension phase of the study.

Additional information, including a detailed description of the study design, eligibility criteria, and investigator sites, is available at ClinicalTrials.gov using identifier NCT03382977.

Poster Presentation/Session Details

-Title: CMV-specific immuno-dysregulation in recurrent glioblastoma patients can be overcome with therapeutic vaccination which is associated with tumor response and overall survival benefits in a Phase I/IIA study
-Abstract: 6538
-Session: Therapeutic Antibodies 5 / Vaccines
-Date: June 22 – 24, 2020
-Event Website: View Source

About the Phase 1/2a Study Design

VBI’s two-part Phase 1/2a study is a multi-center, open-label, dose-escalation study of VBI-1901 in up to 38 patients with recurrent GBM:

●Phase 1 (Part A)

●Dose-escalation phase that defined the safety, tolerability, and optimal dose level of VBI-1901 adjuvanted with granulocyte-macrophage colony-stimulating factor (GM-CSF) in recurrent GBM patients with any number of prior recurrences.
●This phase enrolled 18 recurrent GBM patients across three dose cohorts of VBI-1901: 0.4 µg, 2.0 µg, and 10.0 µg.
●Enrollment completed in December 2018.

●Phase 2a (Part B)

●Subsequent extension of the optimal dose level, 10.0 µg, as defined in the Part A dose escalation phase.
●This phase is a two-arm study, enrolling 10 first-recurrent GBM patients in each arm, assessing 10.0 µg of VBI-1901 in combination with either GM-CSF or GSK’s proprietary AS01B adjuvant system as immunomodulatory adjuvants.
Enrollment of the 10 patients in the GM-CSF arm is complete. Enrollment of the 10 patients in the AS01B arm is ongoing.

VBI-1901 is administered intradermally when adjuvanted with GM-CSF and intramuscularly when adjuvanted with the AS01B adjuvant system. Patients in both phases of the study receive the vaccine immunotherapeutic every four weeks until tumor progression.

About VBI-1901 and GBM

VBI-1901 is a novel cancer vaccine immunotherapeutic candidate developed using VBI’s enveloped virus-like particle (eVLP) technology to target two highly immunogenic cytomegalovirus (CMV) antigens, gB and pp65. Scientific literature suggests CMV infection is prevalent in multiple solid tumors, including glioblastoma (GBM). GBM is among the most common and aggressive malignant primary brain tumors in humans. In the U.S. alone, 12,000 new cases are diagnosed each year. The current standard of care for treating GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and is exceptionally lethal.

Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020

On May 15, 2020 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, reported that an abstract describing the preclinical safety, improved functional characteristics and antitumor efficacy of ATA2271, a next-generation autologous chimeric antigen receptor (CAR) T cell therapy targeting mesothelin, was selected for a late-breaking poster presentation at the second American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting 2020 to be held on June 22-24, 2020 (Press release, Atara Biotherapeutics, MAY 15, 2020, View Source [SID1234558167]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Although CAR T cell therapies have been approved for certain hematologic malignancies, new approaches are needed in solid tumor settings. Mesothelin is a tumor-specific antigen that is commonly expressed at high levels on the cell surface in many aggressive solid tumors including mesothelioma. Atara has selected mesothelin as the target for both the ATA2271 autologous and the ATA 3271 allogeneic programs along with novel CAR T-cell technologies to further enhance activity.

Data being presented for the first time at AACR (Free AACR Whitepaper) detail results from IND-enabling preclinical studies with ATA2271 technologies, designed to help overcome current CAR T challenges with targeting solid tumors, including the novel 1XX CAR signaling domain and a dominant-negative programmed death-1 receptor (PD1DNR). These studies, led by Prasad Adusumilli, MD and collaborators at Memorial Sloan Kettering Cancer Center (MSK) provide both in vitro and in vivo evidence of the preclinical safety, improved functional characteristics and enhanced anti-tumor efficacy of ATA2271.

"These data support the combined addition of novel design elements in this next-gen CAR T therapy, including both 1XX co-stimulatory signaling and PD1DNR, that were associated with less cell exhaustion, improvements in functional persistence, serial cell killing, and in vivo efficacy which was maintained through multiple tumor re-challenges," said Blake T. Aftab, Ph.D., Vice President of Preclinical and Translational Science for Atara Biotherapeutics. "These results are consistent with the larger body of data supporting key CAR T characteristics that are preferred when targeting mesothelioma and potentially a range of solid tumors."

Specifically, in vitro, ATA2271 exhibited antigen-specific cytotoxicity, accumulation and effector cytokine secretion, while in vivo results demonstrated that a single dose of ATA2271 led to tumor eradication and superior survival in mice compared to mesothelin-targeted M28z CAR T cells. Mice treated with a single dose of ATA2271 also showed sustained and persistent protection from tumor reestablishment upon 10 additional tumor re-challenges. Results from the study demonstrated the proposed advantages associated with functional persistence and cell-intrinsic PD-1 checkpoint blockade.

"We look forward to advancing our next-generation CAR T program which includes ATA2271 and off-the-shelf, allogeneic MSLN-directed CAR T immunotherapy, ATA3271, and expanding the investigation of our technology in other mesothelin-expressing solid tumors," said AJ Joshi, MD, Senior Vice President and Chief Medical Officer of Atara Biotherapeutics.

These data will be used to support submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the second or third quarter of 2020 followed by the initiation of a Phase 1 clinical trial in patients with advanced mesothelioma.

About ATA2271

In collaboration with MSK, Atara is developing ATA2271, a next-generation autologous mesothelin-targeted CAR T using novel 1XX CAR signaling and programmed death-1 (PD-1) dominant negative receptor (PD1DNR) checkpoint inhibition technologies (M28z1XX PD1DNR CAR T cells). This technology is supported by the safety and anti-tumor efficacy that was exhibited in prior studies evaluating a mesothelin-directed CAR utilizing a CD28 co-stimulatory signally domain. This regionally delivered autologous mesothelin-targeted construct (using M28z CAR T cells) combined with PD-1 antibody is being studied in two ongoing MSK Phase 1 trials in patients with malignant pleural disease and mesothelioma, non-small cell lung cancer, and breast cancer (NCT02414269 and NCT02792114).

Details of the poster presentation and abstract are as follows:
Abstract #: LB-378
Title: "Regional delivery of clinical-grade mesothelin-targeted CAR T cells with cell-intrinsic PD-1 checkpoint blockade: Translation to a phase I trial"
Presentation Date and Time: Available starting on June 22nd
Session Title: Late-Breaking Research: Immunology 2
Category and Subclass: Immunology
Authors: Stefan Kiesgen, Camille Linot, Hue T. Quach, Jasmeen Saini, Rebecca Bellis, Srijita Banerjee, Zhaohua Hou, Navin K. Chintala, Michel Sadelain, Prasad S. Adusumilli
Affiliations: Memorial Sloan Kettering, New York, NY

Dr. O’Reilly, Dr. Sadelain, and Dr. Adusumilli have intellectual property interests in technologies licensed by Memorial Sloan Kettering (MSK) to Atara. Related to ATA2271 and ATA3271, Dr. Sadelain and Dr. Adusumilli have intellectual property interests in technology licensed by Memorial Sloan Kettering (MSK) to Atara. Dr. O’Reilly and Dr. Adusumilli also have compensated consulting relationships with Atara. MSK has institutional financial interests related to Atara in the form of intellectual property rights and associated interests by virtue of licensing agreements between MSK and Atara.